Monthly Archives: March 2012
Drug Market Info Launches New Prostate Cancer Market Info™
DRUG MARKET INFO LAUNCHES NEW PROSTATE CANCER MARKET INFO™
Comprehensive Presentation-ready Report on Prostate Cancer Covers All Treatment Options and Up-to-date Market Information with Patients’ Perspectives
NORWELL, MA– March 27, 2012- Drug Market Info®, the only source for presentation-ready market reports with the Patient’s Perspective, announced today the launch of its newest research report – Prostate Cancer Market Info™. Prostate cancer is a common cancer found in men, and has the second leading cancer-related mortality rate behind lung cancer. Prostate Cancer Market Info™ is a comprehensive look at the market, including current market data, diagnosis statistics, and treatment options, as well as patient estimates by disease stage.
Prostate Cancer is a malignant adenocarcinoma that grows as small tumors in different locations throughout a man’s prostate gland. Some tumors are indolent and require no treatment, but others are aggressive and life-threatening. Currently, there is no way to tell tumor aggressiveness and no clear guidelines about how to manage the disease, or which treatment option works best. Recently, several new products for the later stages of Prostate Cancer have been launched and according to a recent Barron’s report, the metastatic prostate-cancer market could grow from approximately $1 billion to $8 billion by the end of the decade.
Prostate Cancer Market Info™ provides a comprehensive look at the market, covering epidemiology, patient estimates by disease stage, as well as unit and sales data trended for five years. As a presentation-ready report, Prostate Cancer Market Info™ is the only market analysis that contains over 100 customizable slides, 28 graphs and charts, with patient insights and perspectives woven throughout. As with all Drug Market Info reports, Prostate Cancer Market Info™ was reviewed by a leading clinician in the field to validate disease dynamics and therapeutic approaches.
“Prostate Cancer is a disease that significantly impacts men and their families with one out of every six developing the disease and over two million men in the U.S. currently living with it,” said Mary Beth Cicero, Principal of Drug Market Info. “This new report from Drug Market Info provides unique insights on the diagnosis and treatment of prostate cancer, especially since there are a variety of choices available to physicians and their patients. The Prostate Cancer Market Info™ report examines the current landscape of available treatments and pipeline products, but more importantly, spotlights how real patients weigh their treatment options and ultimately decide upon a regimen that works best for them.”
“We see over 1,000 newly diagnosed prostate cancer patients each year,” said Judd Moul, M.D., F.A.C.S. James H. Semans, MD, Professor of Surgery Director at Duke Cancer Institute. “Every man is different, so his cancer is different and his treatment choices will be, too. Therefore, it is important that a comprehensive array of treatments be available, as well as access to clinical trials and cutting-edge therapies. Drug Market Info’s comprehensive Prostate Cancer Market Info™ thoroughly covers the patients, treatments and what is in the pipeline, and is an important resource for companies looking to better understand this disease.”
Drug Market Info develops reports based on putting patients front and center. We are strong supporters of patient advocacy and our business model is built around donating a portion of our proceeds to the leading patient advocacy group in each therapeutic area we cover. Drug Market Info is extremely proud and privileged to be associated with ZERO — The Project to End Prostate Cancer. The organization is committed to creating Generation Zero: the first generation of men free from prostate cancer. Zero prostate cancer deaths. Zero prostate cancer cases. Zero tolerance for prostate cancer. To accomplish their goal, ZERO provides comprehensive treatment information to patients, education to those at risk and conducts free prostate cancer screening throughout the country. To learn more about ZERO, visit http://zerocancer.org.
“This year alone, more than 241,000 men will be diagnosed with prostate cancer and more than 28,000 will die from the disease,” said Skip Lockwood, Chief Executive Officer of ZERO. “We are seeing the death rate decrease, but we must remain vigilant in the fight against this disease by increasing research funding, raising awareness and education, and testing men with risk factors. We are pleased to be associated with Drug Market Info for making available important data on the prostate cancer market, and for showing how the disease and treatment dramatically affects the lives of men.”
About Drug Market Info (http://www.drugmarketinfo.com/)
Have you ever just wanted to understand a disease – what it looks like, who gets it, what are the treatments, which products are used and how the market is valued? Drug Market Info was founded by experienced pharmaceutical professionals who recognized the need for current, ready-to-use market information that gets to the real core of understanding a therapeutic market. Drug Market Info reports are centered around the concept of the three P’s – Patients, Perspectives and Potential with a strong focus on patient and physician insights. Our reports provide clinically accurate, up-to-date information on treating diseases such as Psoriasis, Psoriatic Arthritis, Cystic Fibrosis and Prostate Cancer, as well as how these markets are defined, sized and valued. Unique from other industry reports on the market, Drug Market Info delivers information in a presentation-ready PowerPoint format at a reasonable price. In just minutes, you can download a customizable deck of slides covering everything you need to know about a therapeutic market and the opportunities it represents. Most importantly, only Drug Market Info provides patients’ perspectives on the disease and their treatment experiences. The Company proudly collaborates with leading Patient Advocacy Groups so that every report purchased will benefit patients with the disease.
Drug Market Info – The Patients’ Perspectives and the Info You Want Now!
For Sales Information, please contact:
Mary Beth Cicero, Principal or Pamela Porter, Chief Business Officer
Call (855) DRUGMKT (378-4658)
Twitter: @DrugMarketInfo
For Media Inquiries, please contact:
Lisa Rivero
(855) 378-4658
The DrugMarketInfo.com Blog 